(Press-News.org) Scientists have found that the diabetes/weight loss drug Semaglutide, sold commercially under brand names like Ozempic and Wegovy, significantly reduces cocaine-seeking behaviour in rats. This work needs to be confirmed in humans, but it suggests that Semaglutide is a candidate to be developed as a treatment for cocaine dependency; at the moment there is no effective pharmacological treatment for cocaine dependency. The work is published in the September edition of the peer-reviewed journal European Neuropsychopharmacology.
Cocaine is the second most popular illegal drug used in Europe. The European Drug Agency reports that around 2.7 million young adults (between the age of 15-34) use cocaine regularly, representing around 2.5% of the population in that age group. Cocaine use in the UK is the second highest in the world, with around 2.7% of adults using the drug (see notes). There is, to date, no effective pharmacological treatment for problematic cocaine use.
Scientists from the University of Gothenburg in Sweden and the University of Pennsylvania, led by Professor Elisabet Jerlhag (University of Gothenburg), gave male rats access to directly-injected cocaine, which they could dispense by pressing a lever in the cage. Then an experimental group of 10 of these animals were treated with semaglutide before being given access to the cocaine dispenser.
Elisabet Jerlhag said:
“We found that in comparison to the control animals, self-administration of cocaine use dropped by 26% in those animals which had been given semaglutide. Previous results, both from our group and from other groups, have found that semaglutide can reduce alcohol consumption and craving in both humans and animals, and this work on cocaine seems to reflect these previous findings on alcohol use. This is the first trial showing Semaglutide’s potential as a drug for cocaine dependence.
Importantly, we also found that after a period of abstinence, there was a 62% drop in cocaine seeking in those animals which had taken semaglutide and the motivation (work undertaken to attain the drug) was lowered by 52%.
This is animal work, so at the moment, we can’t say that we have anywhere near a viable treatment for human cocaine dependency. We need a bigger study to confirm these results, and then we need to see if the findings also apply to humans. However, these results are very promising, underlining the need for human studies, especially since there are no existing pharmacological treatments for cocaine dependency”.
Semaglutide belongs to a class of drugs called GLP-1 inhibitors. These drugs (along with the similar drug Mounjaro) have revolutionised the treatment of excess weight, and are now showing promise in the treatment of mental health problems.
Commenting, Professor Christian Hendershot (of the Institute for Addiction at the Keck School of Medicine, University of Southern California, Los Angeles) said:
“This is a carefully conducted study that provides additional evidence that GLP-1 receptor agonists can reduce cocaine reinforcement. These findings have clinical implications given the challenges identifying medications for stimulant use disorder, and the increasing clinical use of semaglutide in many areas of the world. These findings should encourage clinical trials of GLP-1 receptor agonists for stimulant use disorder”.
Professor Hendershot was not involved in this research; this is an independent comment. Professor Hendershot was lead researcher on the first randomized, placebo-controlled clinical trial of semaglutide’s effects on alcohol craving in adults
Notes
European Statistics https://www.euda.europa.eu/publications/european-drug-report/2025/cocaine_en#edr25-cocaine-prevalence
UK report. https://theweek.com/health/britains-cocaine-habit-use-of-the-drug-is-surging-in-the-uk-with-alarming-consequences
Semaglutine and alcohol https://today.usc.edu/popular-weight-loss-diabetes-drug-shows-promise-in-reducing-cravings-for-alcohol/
Publication details
This paper appears in the September edition of the Journal European Neuropsychopharmacology (an official journal of the ECNP, www.ecnp.eu):
Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens. Cajsa Aranäs , Antonia Caffrey, Christian E. Edvardsson, Heath D. Schmidt, Elisabet Jerlhag
European Neuropsychopharmacology Volume 98, September 2025, Pages 1-10
Paper currently available online at:
https://www.sciencedirect.com/science/article/pii/S0924977X25001300
For funding see paper.
END
Weight-loss drug semaglutide reduces cocaine use in rats: Suggests possible first pharmacological treatment for human cocaine dependency
2025-09-03
ELSE PRESS RELEASES FROM THIS DATE:
Are probiotics worth the cost to prevent infection after a colon removal surgery?
2025-09-03
A new UCLA Health study found that taking an 8-strain probiotic daily may reduce the risk of pouchitis, a common inflammatory condition that occurs after colon removal surgery for ulcerative colitis, but the treatment may not be worth the cost depending on a patient’s likelihood of flare-ups.
The study, published in the journal Gastro Hep Advances, is the first to evaluate the cost-effectiveness of the probiotic treatment, which was shown in previous studies to be effective at preventing the initial onset of and the reoccurrence of pouchitis. The UCLA study affirmed that the ...
Mizzou at the forefront of using hydrogen energy safely
2025-09-03
Researchers at the University of Missouri are working to make hydrogen energy as safe as possible.
As more countries and industries invest heavily in cleaner, renewable energy, hydrogen-powered factories and vehicles are gaining in popularity.
But hydrogen fuel comes with risks — leaks can lead to explosions, accidents and environmental harm.
Most hydrogen-detecting sensors on the market are expensive, can’t operate continuously and aren’t sensitive enough to detect tiny leaks quickly.
That’s why Mizzou’s Xiangqun Zeng and her team in the College of Engineering set out to design the ideal hydrogen sensor, focusing on six traits: sensitivity, ...
New design framework makes it easier to create custom shock-absorbing materials
2025-09-03
MADISON — University of Wisconsin–Madison mechanical engineers have developed a comprehensive framework that accelerates improvements to shock-absorbing foam materials.
The materials have an array of uses ranging from sports or military helmet liners to struts that cushion a spacecraft landing.
“We’ve developed a novel design framework to help designers create a shock-absorbing material of a specific geometry that does exactly what they want it to do without adding weight or ...
Ochsner Health honored by AMA for Joy in Medicine
2025-09-03
Ochsner Health has earned a Gold-level recognition in 2025 from the American Medical Association (AMA) as a Joy in Medicine® organization. The prestigious recognition from the country’s leading physician association honors health systems, hospitals and medical groups that prioritize proven methods to reduce burnout and enhance the professional fulfillment of doctors that comes from patient care. Organizations that meet the rigorous criteria of the Joy in Medicine Health System Recognition Program are leaders in ...
New meta-analysis demonstrates that access to the GeneSight test can significantly improve response and remission rates for patients with depression
2025-09-03
SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSightâ Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual ...
UCLA receives $7.1M federal grant to expand psychotherapy treatment for chronic pain
2025-09-03
UCLA Health has received a $7.1 million grant from the National Institutes of Health to expand research into a newer form of psychotherapy that has been shown to more significantly alleviate chronic pain among older adults compared to traditional cognitive behavioral therapy.
The planned five-year clinical trial will work with nearly 700 war veterans at seven U.S. Department of Veterans Affairs centers throughout the country to evaluate the effectiveness of the therapy, known as emotional awareness and expression therapy (EAET). Developed in the 2010s, EAET aims to show patients that the brain’s perception of pain is strongly influenced by stress-related emotions. ...
One dose of antibiotic treats early syphilis as well as three doses
2025-09-03
EMBARGOED FOR RELEASE
Wednesday, Sept. 3, 2025
5 p.m. Eastern Time
Media Contact:
NIH Office of Communications and Public Liaison
301-496-5787
One dose of antibiotic treats early syphilis as well as three doses
NIH-funded clinical trial shows potential to simplify treatment for early syphilis
Researchers funded by the National Institutes of ...
Researchers identify single antibody behind life-threatening reaction to common blood thinner
2025-09-03
Hamilton, ON (Sept. 3, 2025) --- Researchers at McMaster University have discovered that a rare but dangerous reaction to a widely used blood thinner is caused by a single antibody – overturning decades of medical misunderstanding and opening the door to more precise ways of diagnosing and treating this medical complication.
The study, published in the New England Journal of Medicine on Sept. 3, 2025, focused on heparin-induced thrombocytopenia (HIT), a serious immune complication that affects approximately one per cent of hospitalized patients treated with the blood thinner heparin. Nearly half of those who develop HIT experience life-threatening blood clots, ...
Don’t sweat it: New device detects sweat biomarker at minimal perspiration rate
2025-09-03
UNIVERSITY PARK, Pa. — Available on-demand, in abundance and containing multiple biomarkers, sweat is an increasingly appealing medium for monitoring health, according to researchers at Penn State. But not everyone — especially critically ill patients — can build up enough sweat to provide a robust enough sample for current analysis techniques. That may no longer be an issue, thanks to the team at Penn State that has developed a novel wearable sensor capable of continuously monitoring low rates of perspiration for the presence of a lactate — a molecule ...
Not so sweet: Some sugar substitutes linked to faster cognitive decline
2025-09-03
Highlights:
The study followed 12,772 adults with an average age of 52
Researchers tracked seven artificial sweeteners typically found in ultra-processed foods like flavored water, soda, energy drinks, yogurt and low-calorie desserts
People who consumed the highest total amounts of these sweeteners had faster decline in overall thinking and memory skills compared to people who consumed the lowest amounts
The faster decline equaled about 1.6 years of aging
Researchers found a link in people under 60 but not older than 60
While the study found links, it does not ...